Immunocytokines (Q57911975)

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Antibody targeted drugs as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Neonatal Fc receptor and IgG-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Human antibody-Fc receptor interactions illuminated by crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Epithelial cell adhesion molecule expression (CD326) in cancer: A short review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Lessons from common markers of tumor-initiating cells in solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Jekyll and Hyde: the role of the microenvironment on the progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Targeting the stromal microenvironment in chronic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Angiogenesis in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Antibody-based vascular tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Genes expressed in human tumor endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

A proteomic approach for the identification of vascular markers of liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Cytokines and their relationship to the symptoms and outcome of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Dual roles of immune cells and their factors in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Interleukin-2 in the treatment of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Preclinical safety evaluation of recombinant human interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

A Human mAb Specific to Oncofetal Fibronectin Selectively Targets Chronic Skin Inflammation In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Soluble plasma HLA peptidome as a potential source for cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/ANTIB1010070